Clinical trials: Valvular Cardiomyopathy
Aortic Stenosis, Valvular Cardiomyopathy
Feasibility of 3D Printed Models of Aortic Stenosis in Guiding TAVI Procedure
The aim of 3DP-FAST study is to analyze the accuracy of replicating cardiovascular anatomical structures using different techniques and to evaluate the feasibility of 3D printed models of aortic stenosis in guiding TAVI…
- Conditions
- Aortic Stenosis, Valvular Cardiomyopathy, Aortic Valve Disease
- Trial name
- 3DP-FAST (NCT05484713)
- Testing
- Cardiac imaging, 3D printing of the aortic valve
- Where
- Romania
- Volunteers
- 20 people
- Sponsor
- Cardio Med Medical Center
Rheumatic Fever, Valvular Heart Diseases
Improving Management and Secondary Prevention Through Azithromycin Comparative Trial in Rheumatic Heart Disease in Nigeria)- IMPACT-RHD Nigeria
Background: Nigeria, among other Low and Middle-income countries, bears one of the highest burdens of RHD in Africa, affecting young to middle-aged adults within their productive years.
- Conditions
- Rheumatic Fever, Valvular Heart Diseases, Valvular Cardiomyopathy
- Trial name
- IMPACT-RHD (NCT07625228)
- Testing
- Benzathine Penicillin, Azithromycin (Azithro)
- Volunteers
- 474 people
- Sponsor
- Ladoke Akintola University of Technology, Ogbomoso, Nigeria
Ischemic Mitral Regurgitation
Effect of Ranolazine on Valvular Disease in Patients With Pacemakers
The purpose of this study is to find out whether mitral regurgitation (or a leaky heart valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve after administration of ranolazine.
- Trial name
- REIN-MR (NCT01979965)
- Testing
- Ranolazine (Active drug)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University Cardiology
Coronary Artery Disease, Valvular Heart Disease
Effect of Topical Anesthesia on Hemodynamics During the Induction Period in Patients Undergo Cardiac Surgery.
The aim of the induction is to decrease stress response of endotracheal intubation. It is also important to keep hemodynamics stable during and after the induction period.
- Conditions
- Coronary Artery Disease, Valvular Heart Disease, Arrhythmia, Myocardial Disease
- Trial name
- NCT04744480
- Testing
- The combined topical anesthesia induction group
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Qianfoshan Hospital
Cardiovascular Diseases
DeBakey Cardiovascular Magnetic Resonance Study
While advancements in cardiac magnetic resonance (CMR) have improved image quality, it is unclear how these improvements are connected to the clinical evaluation of individuals with cardiovascular disease.
- Trial name
- DEBAKEY-CMR (NCT04281823)
- Testing
- Cardiovascular Magnetic Resonance
- Where
- United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Dipan Shah
Cardiomyopathy, Cardiovascular Diseases
Improving Mitral Repair for Functional Mitral Regurgitation
The investigators are interested in determining the best surgical technique to correct functional mitral regurgitation, as there is currently not one technique that is established to work better than the other.
- Conditions
- Cardiomyopathy, Cardiovascular Diseases, Congestive Heart Failure, Coronary Artery Disease
- Trial name
- IMPROVE-FMR (NCT03366649)
- Testing
- Undersizing Mitral Annuloplasty, Papillary Muscle Approximation
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Emory University
Coronary Artery Disease, Heart Failure
Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD.
- Conditions
- Coronary Artery Disease, Heart Failure, Hypertrophic Cardiomyopathy, Congenital Heart Disease
- Trial name
- SE2030 (NCT05081115)
- Testing
- ABCDE-Stress Echo, SE diastolic assessment, SE Right ventricular function assessment
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Fatebenefratelli Hospital
Cardiovascular Diseases, Heart Failure
Development of CIRC Technologies
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization.
- Conditions
- Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy
- Trial name
- CIRC (NCT05654272)
- Testing
- MRI
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
In patients with heart failure due to a reversible underlying cause-such as valvular heart disease or coronary artery disease-surgical or procedural correction of the underlying lesion (valve repair/replacement, TAVI, PCI, or…
- Conditions
- Heart Failure Due to Coronary Artery Disease, Valvular Cardiomyopathy, Heart Failure
- Trial name
- NCT07572032
- Testing
- Sacubitril / Valsartan, SGLT-2 inhibitor, SGLT2 Inhibition
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Heart Failure With Reduced Ejection Fraction, Heart Failure
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
This is a multicenter, randomized, open-label pilot study to evaluate whether stepwise withdrawal of two heart failure medications-angiotensin receptor-neprilysin inhibitor (ARNI) and sodium-glucose cotransporter-2 inhibitor…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure, Ventricular Dysfunction, Left
- Trial name
- STEP-DOWN HF (NCT07631156)
- Testing
- Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy
- Where
- 5 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Kyungsub Song
Cardiovascular Diseases, Heart Failure
Longitudinal Validation of CIRC Technologies
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization.
- Conditions
- Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy
- Trial name
- NCT07081711
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Valvular Heart Disease, Pericardial Disease
PPG to Predict Ejection Fraction and Other Echographic Data in the General Population
The investigators are aiming to investigate the association between ejection fraction (EF) determined by echocardiography and signals obtained from Photoplethysmography (PPG) in the general population.
- Conditions
- Valvular Heart Disease, Pericardial Disease, Cardiomyopathies
- Trial name
- NCT04843371
- Testing
- Photoplethysmography
- Where
- 3 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tulane University
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Heart Failure, Valvular Heart Diseases
Observational Study to Validate a Family Physician Echocardiography Training Programme
Observational Study on the Validation of Family Doctors' Training in Echocardiography The Catalan Society of Family and Community Medicine (CAMFiC) developed a structured training program for Family Physicians in focused cardiac…
- Conditions
- Heart Failure, Valvular Heart Diseases, Atrial Fibrillation (AF), Arterial Hypertension
- Trial name
- HEART-CAMFiC (NCT07339007)
- Testing
- Cohort of GPs: Training program, Cohort of patients
- Where
- Spain
- Volunteers
- 500 people
- Sponsor
- Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC)
Valvular Heart Disease, Implantable Cardioverter Defibrillator
Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy
The prevalence of valvular heart disease is on the rise along with the aging society and the generalization of echocardiography.
- Conditions
- Valvular Heart Disease, Implantable Cardioverter Defibrillator, Sudden Cardiac Death, Primary Prevention
- Trial name
- BEAT (NCT03590730)
- Testing
- ICD implantation
- Where
- 12 sites in South Korea
- Volunteers
- 12 people
- Sponsor
- Keimyung University Dongsan Medical Center